Generics Market Still Dominated By Local Firms

Brazil's rapidly growing generics market is clearly attractive to multinational pharmaceutical companies. BMI data show that sales of generic drugs grew at a compound annual growth rate (CAGR) of 25.7% from 2003-2008. Sanofi-Aventis's acquisition of domestic firm Medley confirmed the current appetite for the sector, while Pfizer is reportedly interested in buying NeoQuimica for US$525mn. However, the government has indicated that it may look to restrict foreign takeovers of domestic firms in order to prevent denationalisation that may restrict future acquisitions. Here BMI assesses the competitive landscape of Brazil's generic drug sector and the current and future beneficiaries of this

To read the full article, please choose one of the following options: